RECURRENT DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for RECURRENT DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy combo shows promise against rare sarcomas before surgery
Disease control OngoingThis study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) and radiation before surgery can help shrink tumors in people with two rare types of sarcoma. About 32 adults with these sarcomas that can be removed by surgery will take part. The goal is …
Matched conditions: RECURRENT DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
New drug duo targets hard-to-treat sarcoma
Disease control OngoingThis study tests whether combining two drugs (etrumadenant and zimberelimab) can shrink tumors or slow the disease in people with advanced dedifferentiated liposarcoma that has returned, spread, or cannot be removed by surgery. About 16 adults with this rare soft-tissue cancer wi…
Matched conditions: RECURRENT DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New drug combo aims to fight rare cancers that Won't go away
Disease control OngoingThis study tests whether two immunotherapy drugs, oleclumab and durvalumab, can shrink or slow the growth of certain sarcomas (angiosarcoma, liposarcoma, and osteosarcoma) that have come back, spread, or stopped responding to standard treatment. About 75 adults and some teens (ag…
Matched conditions: RECURRENT DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC